Ridgeback Capital Investments L.P. reported 1 positions worth $80.93M for the quarter ended Jun 30, 2026. Its largest holding is Replimune Group, Inc. at 100% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | REPL Replimune Group, Inc. | Healthcare | 7.31M | $80.93M | 100% | – | – | – | 7.55% |
Tip. Select a row to see that position’s full history at Ridgeback Capital Investments.
As of its Q2 2026 13F filing, Ridgeback Capital Investments L.P.’s five largest positions were Replimune Group, Inc. (REPL) at 100.0% of the reported portfolio.
Ridgeback Capital Investments L.P. reported a 13F portfolio worth $80.93M across 1 positions for Q2 2026.
From the Form 13F-HR reports Ridgeback Capital Investments L.P. files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.